Efficacy and safety of mycophenolate mofetil for steroid reduction in neuromyelitis optica spectrum disorder: a prospective cohort study

References

• Miyamoto K. Epidemiology of multiple sclerosis and neuromyelitis optica. Nihon Rinsho. 2014;72(11):1903–1907.
   PubMedGoogle Scholar
• Papp V, Magyari M, Aktas O, et al. Worldwide incidence and prevalence of neuromyelitis optica: a systematic review. Neurology. 2021;96(2):59–77. doi: 10.1212/WNL.0000000000011153.
   PubMed Web of Science ®Google Scholar
• Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66(10):1485–1489. doi: 10.1212/01.wnl.0000216139.44259.74.
   PubMed Web of Science ®Google Scholar
• Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364(9451):2106–2112. doi: 10.1016/S0140-6736(04)17551-X.
   PubMed Web of Science ®Google Scholar
• Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202(4):473–477. doi: 10.1084/jem.20050304.
   PubMed Web of Science ®Google Scholar
• Cree BAC, Bennett JL, Kim HJ, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet. 2019;394(10206):1352–1363. doi: 10.1016/S0140-6736(19)31817-3.
   PubMed Web of Science ®Google Scholar
• Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in aquaporin-4-Positive neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(7):614–625. doi: 10.1056/NEJMoa1900866.
   PubMed Web of Science ®Google Scholar
• Yamamura T, Kleiter I, Fujihara K, et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(22):2114–2124. doi: 10.1056/NEJMoa1901747.
   PubMed Web of Science ®Google Scholar
• Huh SY, Kim SH, Hyun JW, et al. Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder. JAMA Neurol. 2014;71(11):1372–1378. doi: 10.1001/jamaneurol.2014.2057.
   PubMed Web of Science ®Google Scholar
• Jacob A, Matiello M, Weinshenker BG, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol. 2009;66(9):1128–1133. doi: 10.1001/archneurol.2009.175.
   PubMedGoogle Scholar
• Jeong IH, Park B, Kim SH, et al. Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints. Mult Scler. 2016;22(3):329–339. doi: 10.1177/1352458515587752.
   PubMed Web of Science ®Google Scholar
• Jiao Y, Cui L, Zhang W, et al. Dose effects of mycophenolate mofetil in chinese patients with neuromyelitis optica spectrum disorders: a case series study. BMC Neurol. 2018;18(1):47. doi: 10.1186/s12883-018-1056-x.
   PubMedGoogle Scholar
• Mealy MA, Wingerchuk DM, Palace J, et al. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol. 2014;71(3):324–330. doi: 10.1001/jamaneurol.2013.5699.
   PubMed Web of Science ®Google Scholar
• Montcuquet A, Collongues N, Papeix C, et al. Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders. Mult Scler. 2017;23(10):1377–1384. doi: 10.1177/1352458516678474.
   PubMed Web of Science ®Google Scholar
• Torres J, Pruitt A, Balcer L, et al. Analysis of the treatment of neuromyelitis optica. J Neurol Sci. 2015;351(1-2):31–35. doi: 10.1016/j.jns.2015.02.012.
   PubMed Web of Science ®Google Scholar
• Yang Y, Chen L, Wu L, et al. Effective rituximab treatment in patients with neuromyelitis optica spectrum disorders compared with azathioprine and mycophenolate. Neurol Ther. 2022;11(1):137–149. doi: 10.1007/s40120-021-00298-5.
   PubMed Web of Science ®Google Scholar
• Zhang L, Tian J, Dong X, et al. Efficacy of azathioprine, mycophenolate mofetil, and rituximab in the treatment of neuromyelitis optica spectrum disorder and analysis of prognostic factors. Neurol Sci. 2022;43(4):2651–2658. doi: 10.1007/s10072-021-05609-0.
   PubMed Web of Science ®Google Scholar
• Xu Y, Wang Q, Ren HT, et al. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and cyclophosphamide among patients with neuromyelitis optica spectrum disorder: a prospective cohort study. J Neurol Sci. 2016;370:224–228. doi: 10.1016/j.jns.2016.09.035.
   PubMed Web of Science ®Google Scholar
• Yang Y, Wang CJ, Wang BJ, et al. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder. J Neurol Sci. 2018;385:192–197. doi: 10.1016/j.jns.2017.12.034.
   PubMed Web of Science ®Google Scholar
• Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47(2-3):85–118. doi: 10.1016/s0162-3109(00)00188-0.
   PubMed Web of Science ®Google Scholar
• Songwisit S, Kosiyakul P, Jitprapaikulsan J, et al. Efficacy and safety of mycophenolate mofetil therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. Sci Rep. 2020;10(1):16727. doi: 10.1038/s41598-020-73882-8.
   PubMed Web of Science ®Google Scholar
• Huang Q, Wang J, Zhou Y, et al. Low-Dose mycophenolate mofetil for treatment of neuromyelitis optica spectrum disorders: a prospective multicenter study in South China. Front Immunol. 2018;9:2066. doi: 10.3389/fimmu.2018.02066.
   PubMed Web of Science ®Google Scholar
• Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177–189. doi: 10.1212/WNL.0000000000001729.
   PubMed Web of Science ®Google Scholar
• Watanabe S, Misu T, Miyazawa I, et al. Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis. Mult Scler. 2007;13(8):968–974. doi: 10.1177/1352458507077189.
   PubMed Web of Science ®Google Scholar
• Sharrack B, Hughes RA. The guy’s neurological disability scale (GNDS): a new disability measure for multiple sclerosis. Mult Scler. 1999;5(4):223–233. doi: 10.1177/135245859900500406.
   PubMed Web of Science ®Google Scholar
• Wang Y, Ma J, Chang H, et al. Efficacy of mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorders: an update systematic review and meta -analysis. Mult Scler Relat Disord. 2021;55:103181. doi: 10.1016/j.msard.2021.103181.
   PubMed Web of Science ®Google Scholar
• Luo J, Yu J, Sui Z, et al. Comparison on the effect of seven drugs to prevent relapses of neuromyelitis optica spectrum disorders: a modeling analysis of literature aggregate data. Int Immunopharmacol. 2022;110:109004. doi: 10.1016/j.intimp.2022.109004.
   PubMed Web of Science ®Google Scholar
• Espiritu AI, Pasco PMD. Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: a systematic review and meta-analysis. Mult Scler Relat Disord. 2019;33:22–32. doi: 10.1016/j.msard.2019.05.011.
   PubMed Web of Science ®Google Scholar
• Yin Z, Qiu Y, Duan A, et al. Different monoclonal antibodies and immunosuppressants administration in patients with neuromyelitis optica spectrum disorder: a bayesian network meta-analysis. J Neurol. 2023;270(6):2950–2963. doi: 10.1007/s00415-023-11641-1.
   PubMed Web of Science ®Google Scholar
• Poupart J, Giovannelli J, Deschamps R, et al. Evaluation of efficacy and tolerability of first-line therapies in NMOSD. Neurology. 2020;94(15):e1645–e56. doi: 10.1212/WNL.0000000000009245.
   PubMed Web of Science ®Google Scholar
• Aungsumart S, Apiwattanakul M. Cost effectiveness of rituximab and mycophenolate mofetil for neuromyelitis optica spectrum disorder in Thailand: economic evaluation and budget impact analysis. PLOS One. 2020;15(2):e0229028. doi: 10.1371/journal.pone.0229028.
   PubMed Web of Science ®Google Scholar
• Yang SK, Hong M, Baek J, et al. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat Genet. 2014;46(9):1017–1020. doi: 10.1038/ng.3060.
   PubMed Web of Science ®Google Scholar
• Chen H, Zhang Y, Shi Z, et al. The efficacy and tolerability of mycophenolate mofetil in treating neuromyelitis optica and neuromyelitis optica spectrum disorder in Western China. Clin Neuropharmacol. 2016;39(2):81–87. doi: 10.1097/WNF.0000000000000131.
   PubMed Web of Science ®Google Scholar
• Lu A, Zimmermann HG, Specovius S, et al. Astrocytic outer retinal layer thinning is not a feature in AQP4-IgG seropositive neuromyelitis optica spectrum disorders. J Neurol Neurosurg Psychiatry. 2022;93(2):188–195. doi: 10.1136/jnnp-2021-327412.
   PubMed Web of Science ®Google Scholar
• Oertel FC, Specovius S, Zimmermann HG, et al. Retinal optical coherence tomography in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm. 2021;8(6):e1068. doi: 10.1212/NXI.0000000000001068.
   PubMed Web of Science ®Google Scholar
• Pisa M, Ratti F, Vabanesi M, et al. Subclinical neurodegeneration in multiple sclerosis and neuromyelitis optica spectrum disorder revealed by optical coherence tomography. Mult Scler. 2020;26(10):1197–1206. doi: 10.1177/1352458519861603.
   PubMed Web of Science ®Google Scholar
• Castrogiovanni N, Mostert J, Repovic P, et al. Longitudinal changes in cognitive test scores in patients with Relapsing-Remitting multiple sclerosis: an analysis of the DECIDE dataset. Neurology. 2023;101(1):e1–e11. doi: 10.1212/WNL.0000000000207301.
   PubMed Web of Science ®Google Scholar
• Akaishi T, Nakashima I, Takahashi T, et al. Neuromyelitis optica spectrum disorders with unevenly clustered attack occurrence. Neurol Neuroimmunol Neuroinflamm. 2020;7(1):e640. doi: 10.1212/NXI.0000000000000640.
   PubMed Web of Science ®Google Scholar
• Cree B. Mycophenolate mofetil to treat neuromyelitis optica: is it time for a randomized trial? JAMA Neurol. 2014;71(11):1354–1357. doi: 10.1001/jamaneurol.2014.2359.
   PubMed Web of Science ®Google Scholar